Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

BACKGROUND: Lupus animal model has shown that arsenic trioxide (ATO), a treatment of acute promyelocytic leukaemia, could be effective in SLE. This is the first clinical study to determine the safety and efficacy of a short course of intravenous ATO in patients with active SLE. METHODS: This phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamidou, Mohamed, Néel, Antoine, Poupon, Joel, Amoura, Zahir, Ebbo, Mikael, Sibilia, Jean, Viallard, Jean-Francois, Gaborit, Benjamin, Volteau, Christelle, Hardouin, Jean Benoit, Hachulla, Eric, Rieger, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927234/
https://www.ncbi.nlm.nih.gov/pubmed/33658052
http://dx.doi.org/10.1186/s13075-021-02454-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927234/
https://www.ncbi.nlm.nih.gov/pubmed/33658052
http://dx.doi.org/10.1186/s13075-021-02454-6

Ejemplares similares